Clinical Trials

68 results for Prostate Cancer


A Phase 2 Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer and Germline or Somatic DNA Repair Deficiency

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Carboplatin, Drug: Docetaxel
  • Study ID: NCT02985021
View Trial

STAMPEDE: Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy - Androgen Suppression-Based Therapy Alone or Combined With Zoledronic Acid, Docetaxel, Prednisolone, Celecoxib, Abiraterone, Enzalutamide and/or Radiotherap

  • Condition: Prostate Cancer
  • Intervention: Drug: celecoxib, Drug: docetaxel, Drug: prednisolone, Drug: ADT, Drug: zoledronic acid, Drug: abiraterone, Procedure: orchiectomy, Radiation: Radiotherapy to the prostate, Drug: enzalutamide
  • Study ID: NCT00268476
View Trial

A Pilot Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer Containing Biallelic Inactivation of Genes in the BRCA1/2 Pathway

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Carboplatin, Drug: Docetaxel, Other: Laboratory Biomarker Analysis
  • Study ID: NCT02598895
View Trial

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

  • Condition: Prostatic Neoplasms
  • Intervention: Biological: Pembrolizumab 200 mg, Drug: Olaparib 400 mg, Drug: Docetaxel 75 mg/m^2, Drug: Prednisone 5 mg, Drug: Enzalutamide 160 mg, Other: Dexamethasone 8 mg
  • Study ID: NCT02861573
View Trial

TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency

  • Condition: Metastatic Castration Resistant Prostate Cancer
  • Intervention: Drug: Rucaparib, Drug: Abiraterone acetate or Enzalutamide or Docetaxel
  • Study ID: NCT02975934
View Trial

A Randomized Phase 2 Trial of Ascorbic Acid in Combination With Docetaxel in Men With Metastatic Prostate Cancer

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Dietary Supplement: Ascorbic Acid, Drug: Docetaxel, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Placebo, Other: Quality-of-Life Assessment
  • Study ID: NCT02516670
View Trial

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

  • Condition: Prostate Cancer
  • Intervention: Drug: Ra223, Drug: Enzalutamide
  • Study ID: NCT02194842
View Trial

A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)

  • Condition: Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
  • Intervention: Drug: enzalutamide, Drug: mifepristone, Other: laboratory biomarker analysis, Other: pharmacological study
  • Study ID: NCT02012296
View Trial

INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer

  • Condition: Prostate Cancer Metastatic
  • Intervention: Behavioral: High intensity aerobic and resistance training, Behavioral: Psychosocial support
  • Study ID: NCT02730338
View Trial

INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Intervention: Drug: Isovue-M 200
  • Study ID: NCT03071328
View Trial

Registry of Treatment Outcomes in a Non-study Population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223

  • Condition: Prostate Cancer Metastatic, Bone Metastases
  • Intervention: Diagnostic Test: Blood tests
  • Study ID: NCT03223727
View Trial

Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

  • Condition: Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
  • Intervention: Biological: GnRH agonist/antagonist, Drug: Prednisone, Drug: Abiraterone Acetate, Drug: Enzalutamide
  • Study ID: NCT03016741
View Trial

Phase 2 Open Label Study of Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

  • Condition: Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
  • Intervention: Drug: Pembrolizumab, Drug: Chemotherapy
  • Study ID: NCT03248570
View Trial

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

  • Condition: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
  • Intervention: Drug: Abiraterone, Drug: Bicalutamide, Drug: Degarelix, Drug: Docetaxel, Drug: Flutamide, Drug: Goserelin Acetate, Drug: Histrelin Acetate, Drug: Leuprolide Acetate, Drug: Nilutamide, Procedure: Orchiectomy, Drug: Prednisone, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Procedure: Radical Prostatectomy, Drug: Triptorelin
  • Study ID: NCT03678025
View Trial

Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial

  • Condition: Prostate Cancer Metastatic
  • Intervention: Procedure: radical prostatectomy, Radiation: Whole pelvis radiotherapy
  • Study ID: NCT03655886
View Trial

PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

  • Condition: ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal
  • Intervention: Drug: Carboplatin, Drug: Docetaxel, Other: Laboratory Biomarker Analysis, Drug: Rucaparib Camsylate
  • Study ID: NCT03442556
View Trial

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

  • Condition: Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Olaparib, Drug: Abiraterone Acetate, Drug: Prednisone
  • Study ID: NCT03012321
View Trial

High Dose Testosterone in Men With Advanced Prostate Cancer and Homologous Recombination Deficiency

  • Condition: Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
  • Intervention: Drug: Testosterone Enanthate
  • Study ID: NCT03522064
View Trial

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Condition: Prostate Cancer
  • Intervention: Drug: Docetaxel 75 mg/m2, Drug: Docetaxel 60 mg/m2, Drug: Radium-223
  • Study ID: NCT03574571
View Trial

A Phase 1, Open-Label, Non-Randomized, Safety, Tolerability and Pharmacokinetic Study of TAS3681 in Patients With Metastatic Castration Resistant Prostate Cancer

  • Condition: Metastatic Castration Resistant Prostate Cancer
  • Intervention: Drug: TAS3681
  • Study ID: NCT02566772
View Trial

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Prog

  • Condition: Prostatic Neoplasms
  • Intervention: Biological: Pembrolizumab, Drug: Docetaxel, Drug: Prednisone, Drug: Placebo, Drug: Dexamethasone
  • Study ID: NCT03834506
View Trial

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair

  • Condition: Prostatic Neoplasms
  • Intervention: Biological: Pembrolizumab, Drug: Olaparib, Drug: Abiraterone acetate, Drug: Prednisone, Drug: Enzalutamide
  • Study ID: NCT03834519
View Trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib In Combination With Physician's Choice Of Enzalutamide Or Abiraterone Acetate/Prednisone In Metastatic Castration-resistant Prostate Cancer With Dna Damage Repair Deficiencies

  • Condition: DDR+ mCRPC
  • Intervention: Drug: Talazoparib with NHT, Drug: Placebo with NHT
  • Study ID: NCT03395197
View Trial

Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: Radium-223, Drug: Docetaxel
  • Study ID: NCT03230734
View Trial

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer

  • Condition: Metastatic Prostate Cancer
  • Intervention: Drug: Niraparib, Drug: Abiraterone Acetate, Drug: Prednisone, Drug: Placebo
  • Study ID: NCT03748641
View Trial

A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

  • Condition: Prostatic Neoplasms, Castration-Resistant
  • Intervention: Drug: Niraparib 200 mg, Drug: JNJ-63723283 240 mg, Drug: JNJ-63723283 480 mg, Drug: JNJ-63723283 Dose to be Determined
  • Study ID: NCT03431350
View Trial

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

  • Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • Intervention: Drug: Olaparib, Combination Product: 177Lu-PSMA
  • Study ID: NCT03874884
View Trial

A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)

  • Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression
  • Intervention: Other: Laboratory Biomarker Analysis, Drug: Olaparib, Radiation: Radium Ra 223 Dichloride
  • Study ID: NCT03317392
View Trial

Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)

  • Condition: Prostate Cancer
  • Intervention: Drug: Nivolumab
  • Study ID: NCT03040791
View Trial

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

  • Condition: Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer
  • Intervention: Drug: Nivolumab, Drug: Ipilimumab
  • Study ID: NCT03570619
View Trial

Clinical Trial of a Rapidly Cycling, Non-Cross Reactive Regimen of Approved Therapeutic Agents to Treat Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Abiraterone acetate, Drug: Prednisone, Drug: Radium-223 dichloride, Drug: cabazitaxel, Drug: Carboplatin, Drug: Enzalutamide
  • Study ID: NCT02903160
View Trial

Ice-CAP: A Phase I Trial of Ipatasertib in Combination With Atezolizumab in Patients With Advanced Solid Tumours With PI3K Pathway Hyperactivation

  • Condition: Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
  • Intervention: Drug: ipatasertib, Drug: Atezolizumab
  • Study ID: NCT03673787
View Trial

Randomized Phase IB/II Study of Enzalutamide With and Without Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
  • Intervention: Drug: Enzalutamide, Drug: Ribociclib
  • Study ID: NCT02555189
View Trial

A Phase 1, Open-label, First-in-human, Multi-center, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, BAY 2315497 Injection, in Patients With Metastatic Castration

  • Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • Intervention: Drug: BAY 2315497 Injection
  • Study ID: NCT03724747
View Trial

A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Are 18F-DCFPyL Prostate-specific Membrane Antigen

  • Condition: Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate, Progressive mCRPC
  • Intervention: Drug: I-131-1095, Drug: Enzalutamide
  • Study ID: NCT03939689
View Trial

Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer

  • Condition: Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
  • Intervention: Drug: Enzalutamide, Other: Laboratory Biomarker Analysis, Radiation: Radium Ra 223 Dichloride
  • Study ID: NCT03344211
View Trial

A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Tazemetostat, Drug: Abiraterone/prednisone, Drug: Enzalutamide
  • Study ID: NCT04179864
View Trial

177Lu-PSMA-I&T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: 177 Lu-PSMA-I&T
  • Study ID: NCT04188587
View Trial

Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC): Efficacy and Toxicity Evaluation

  • Condition: Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive
  • Intervention: Drug: 177Lu-PSMA
  • Study ID: NCT03454750
View Trial

Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of KPG-121 in Combination With Enzalutamide in Adults With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Intervention: Combination Product: KPG-121 dose escalation + Enzalutamide
  • Study ID: NCT03569280
View Trial

A Phase I Clinical Study of Abiraterone Combined With SHR3162 in the Treatment of Metastatic Castration-resistant Prostate Cancer

  • Condition: Prostate Cancer Castration-resistant Prostate Cancer
  • Intervention: Drug: Abiraterone+SHR3162
  • Study ID: NCT04108247
View Trial

A Phase 2 Study of a Checkpoint Inhibitor in Men With Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

  • Condition: Metastatic Castration Resistant Prostate Cancer
  • Intervention: Drug: Pembrolizumab
  • Study ID: NCT04104893
View Trial

Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

  • Condition: Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
  • Intervention: Biological: pTVG-HP, Biological: pTVG-AR, Drug: Pembrolizumab, Drug: rhGM-CSF
  • Study ID: NCT04090528
View Trial

A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Condition: Prostate Cancer Metastatic
  • Intervention: Drug: FOR46
  • Study ID: NCT03575819
View Trial

A Phase 1b/2 Study to Evaluate the Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

  • Condition: Metastatic Castration Resistant Prostate Cancer
  • Intervention: Drug: VERU-111
  • Study ID: NCT03752099
View Trial

ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castration-Resistant Prostatic Cancer
  • Intervention: Drug: Enzalutamide Oral Capsule [Xtandi], Drug: Abiraterone Oral Tablet [Zytiga], Drug: Carboplatin, Drug: Cabazitaxel 60 mg Solution for Injection, Drug: Docetaxel Injectable Solution, Drug: Radium Chloride Ra-223
  • Study ID: NCT03903835
View Trial

An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone or Enzalutamide

  • Condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
  • Intervention: Drug: GT0918
  • Study ID: NCT03899467
View Trial

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Biological: nivolumab, Drug: prednisone, Drug: docetaxel
  • Study ID: NCT04100018
View Trial

A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: Phase I and Phase II: LAE001/prednisone + afuresertib
  • Study ID: NCT04060394
View Trial

A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Condition: Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplas
  • Intervention: Biological: P-PSMA-101 CAR-T cells, Drug: Rimiducid
  • Study ID: NCT04249947
View Trial